<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Fedullo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary thromboendarterectomy (PTE; also known as pulmonary endarterectomy) is the only definitive therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH) [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         Preparation for PTE, postoperative management, and outcomes following PTE are reviewed here. Initial management of CTEPH, patient selection for PTE, and treatment of CTEPH with pulmonary hypertension-specific therapy are described separately. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
         The approach outlined in this topic is, for the most part, consistent with guidelines set out by several international societies [
         <a href="#rid4">
          4-7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with chronic thromboembolic pulmonary hypertension (CTEPH), the decision to proceed with pulmonary thromboendarterectomy (PTE) is complex and best undertaken at a center experienced in the care of these patients. The decision is based upon the location and extent of chronic thromboembolic obstruction, the associated hemodynamic impairment, and comorbidities that might contribute to the risk of surgery (
         <a class="graphic graphic_algorithm graphicRef131060" href="/z/d/graphic/131060.html" rel="external">
          algorithm 1
         </a>
         ). Details of this evaluation are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Evaluation for pulmonary thromboendarterectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SPECIFIC PREOPERATIVE ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with chronic thromboembolic pulmonary hypertension (CTEPH), we evaluate for general, cardiac, pulmonary, and other factors that may contribute to the risk of pulmonary thromboendarterectomy (PTE). Evaluation for PTE-specific factors, including the need for coronary angiography and an inferior vena cava (IVC) filter, is discussed in this section, while general preoperative assessment is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4815.html" rel="external">
          "Overview of the principles of medical consultation and perioperative medicine"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6917.html" rel="external">
          "Evaluation of perioperative pulmonary risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13516.html" rel="external">
          "Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">
          "Preoperative evaluation and perioperative management of patients with rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1315.html" rel="external">
          "Preoperative assessment of bleeding risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3787516639">
         <span class="h2">
          Coronary angiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are at risk for coronary artery disease (CAD) in whom PTE is planned, we perform coronary angiography prior to surgery. This is often done at the same time as right heart catheterization and pulmonary angiography when assessing a patient’s suitability for PTE. CAD is treated prior to PTE but if indicated, coronary artery bypass grafting can be performed during the same operation as PTE [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery"
         </a>
         .)
        </p>
        <p>
         Data to support this practice are limited. In one review that evaluated routine coronary angiography in 462 patients prior to PTE, significant CAD was detected in 16 percent of patients who were ≥50 years of age. CAD was found in only 5 percent of patients &lt;50 years of age; furthermore, significant CAD was only found in those with three or more coronary risk factors present (diabetes, hypertension, hyperlipidemia, body mass index [BMI] &gt;25 kg/m
         <sup>
          2
         </sup>
         , tobacco use, or a family history of CAD) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16748912">
         <span class="h2">
          Inferior vena cava filter placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         While in the past it was routine, we now no longer routinely place IVC filters prior to PTE since our clinical experience suggests they are not necessary and patients are typically anticoagulated indefinitely.
        </p>
        <p>
         However, in patients with an unusually high risk of thromboembolic recurrence, we sometimes place a temporary IVC filter prior to surgery (eg, those with a recent episode of acute, proximal lower extremity venous thrombosis) [
         <a href="#rid10">
          10
         </a>
         ]. Under this unusual circumstance, a retrievable IVC filter can be placed several days prior to surgery in order to avoid bleeding complications at the insertion-site during the perioperative period [
         <a href="#rid1">
          1
         </a>
         ]. A percutaneous transjugular approach is preferred in order to avoid lower extremity insertion site thrombosis.
        </p>
        <p>
         Details regarding placement of IVC filters and their complications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">
          "Placement of vena cava filters and their complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SURGICAL TECHNIQUE
         </span>
        </p>
        <p class="headingAnchor" id="H375279319">
         <span class="h2">
          Pre-operative management of anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We discontinue anticoagulant therapy (eg,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         or direct oral anticoagulation [DOAC]) at least three days prior to pulmonary thromboendarterectomy (PTE) and use bridging therapy with subcutaneous low molecular weight heparin (LMWH) until the day prior to surgery. (See
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H763892557">
         <span class="h2">
          Standardized approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although subject to minor variation, the surgical approach pioneered at the University of California, San Diego has been standardized over the past decade and involves the following elements [
         <a href="#rid1">
          1,4,11-16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Median sternotomy
         </strong>
         – A median sternotomy allows access to both pulmonary arteries intrapericardially without having to breach the pleural space. It also assures more complete removal of the chronically obstructing material and decreases the likelihood that bronchial artery collateral flow will be disrupted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Double lung ventilation
         </strong>
         – Most patients undergo double lung ventilation for PTE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiopulmonary bypass with periods of deep hypothermic circulatory arrest
         </strong>
         - Cardiopulmonary bypass with periodic hypothermic circulatory arrest provides the bloodless operative field essential for meticulous lobar and segmental dissections of the chronic thromboembolic material.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Periods of circulatory arrest are limited to 20-minute intervals. After each period of circulatory arrest, reperfusion is carried out until either the pulmonary venous saturations reach 90 percent or at least 10 minutes have passed. At the completion of the unilateral or bilateral PTE, circulation is re-established and the patient is rewarmed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dissection of the pulmonary artery and removal of chronic thrombus –
         </strong>
         The main, lobar, and segmental branches of typically both pulmonary arteries are targeted for endarterectomy. An entire unilateral endarterectomy can usually be accomplished by an experienced surgeon within a single 20-minute period of hypothermic circulatory arrest.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Endarterectomy is started by separating the adventitia from the media circumferentially at the most proximal aspect of the surgically visualized chronic thrombus. This requires careful dissection of chronic endothelialized material from the native intima. There are several levels within the vessel where an endarterectomy plane can be established, but only one will strip easily away from the underlying media. Establishing the correct plane is essential. A plane that is too deep results in perforation of the vessel, while a plane that is too superficial will not result in an adequate endarterectomy. Once this plane is identified proximally, dissection is continued distally into the segmental and subsegmental branches (
         <a class="graphic graphic_picture graphicRef78850" href="/z/d/graphic/78850.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atrial septum inspection
         </strong>
         – Following dissection, the atrial septum is routinely inspected, since a previously unidentified atrial septal defect (ASD) or patent foramen ovale is uncovered during surgery in approximately 25 percent of cases and can often be repaired during the same operative setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional procedures
         </strong>
         – Additional procedures that are indicated, such as ASD repair, coronary bypass grafting, or valve replacement, are performed after dissection and rewarming.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3331394882">
         <span class="h2">
          Alternative techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several alternative techniques have been explored in an effort to reduce the neurologic complications of hypothermia and circulatory arrest, but none have proven superior to the traditional technique [
         <a href="#rid1">
          1
         </a>
         ]. These include the use of moderate rather than deep hypothermia, aortic bronchial artery occlusion with a balloon catheter, antegrade cerebral artery perfusion with and without total circulatory arrest, and the application of negative pressure in the left ventricle [
         <a href="#rid17">
          17-19
         </a>
         ]. The theoretical advantage of these alternatives is that surgery can be prolonged to achieve a more precise and complete removal of thrombotic material including the removal of more distal thrombus [
         <a href="#rid20">
          20
         </a>
         ], and that cerebral perfusion may be better preserved.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          POSTOPERATIVE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary thromboendarterectomy (PTE), vigilant postoperative monitoring is necessary because the postoperative course can be complex and it is the period of greatest mortality [
         <a href="#rid21">
          21
         </a>
         ]. Early management should focus on providing adequate oxygenation, optimizing right ventricular preload, and providing inotropic support. Management of an acute pulmonary hypertensive crisis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Management of acute pulmonary hypertensive crisis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3730627397">
         <span class="h2">
          Intensive care unit postoperative care
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients require intensive care unit (ICU) admission following surgery and are typically intubated and mechanically ventilated. Veno-veno-extracorporeal membrane oxygenation (V-V ECMO) is rarely needed, although veno-arterial ECMO (V-A ECMO) is more commonly required perioperatively [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         In the immediate postoperative period, patients typically have the following in place:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pulmonary artery catheter to monitor cardiac output and pulmonary artery pressure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A Foley catheter to monitor urine output
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Temporary transcutaneous pacing wires
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An arterial catheter to monitor systemic blood pressure and provide access for arterial blood gas measurements
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One or more mediastinal tubes to aid with mediastinal drainage
        </p>
        <p>
        </p>
        <p>
         A daily assessment is performed that includes a physical examination, routine laboratories, coagulation studies, and, if indicated, an electrocardiogram or chest radiograph. Echocardiography is not routinely performed unless a cardiac complication was suspected (eg, acute myocardial infarction). Careful ICU monitoring during the early postoperative period is critical since two phenomena, pulmonary artery steal and reperfusion pulmonary edema (RPE), can occur during this early period. Both conditions can occur in isolation or together and can result in profound hypoxemia. These conditions are described below. (See
         <a class="local">
          'Monitoring for pulmonary endarterectomy-specific complications'
         </a>
         below.)
        </p>
        <p>
         Balloon inflation of the Swan Ganz catheter is not performed due to the risk of disruption of the pulmonary artery suture lines. The Swan Ganz catheter is typically removed when vasoactive medication support is able to be discontinued. (See
         <a class="medical medical_review" href="/z/d/html/1593.html" rel="external">
          "Pulmonary artery catheterization: Indications, contraindications, and complications in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1658.html" rel="external">
          "Pulmonary artery catheters: Insertion technique in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1595.html" rel="external">
          "Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults"
         </a>
         .)
        </p>
        <p>
         Pacer wires are removed when a stable sinus rhythm has been achieved. (See
         <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">
          "Temporary cardiac pacing"
         </a>
         .)
        </p>
        <p>
         Extubation is undertaken, usually on the first or second postoperative day in the majority of patients, when the patient is awake and alert and gas exchange is adequate such that mechanical ventilatory support is no longer required. (See
         <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">
          "Extubation management in the adult intensive care unit"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">
          "Initial weaning strategy in mechanically ventilated adults"
         </a>
         .)
        </p>
        <p>
         Once patients are extubated, they can be transferred to the floor for further monitoring including telemetry given the risk of postoperative atrial arrhythmias. The median ICU length of stay is approximately three to four days, with a total postoperative hospital length of stay of 10 to14 days.
        </p>
        <p class="headingAnchor" id="H4793743">
         <span class="h2">
          Venous thromboembolism prophylaxis and resumption of therapeutic anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CTEPH are at high postoperative risk of recurrent thromboembolism. For the majority of patients, we initiate pharmacologic thromboprophylaxis 8 to 12 hours after the surgical procedure provided there are no contraindications and the mediastinal output has decreased to approximately 30 mL/hour.
        </p>
        <p>
         Prophylactic anticoagulation can be provided in a variety of ways, but our method of choice is intravenous
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         targeting an anti-Xa level in the low therapeutic range (0.3 to 0.5 international units/mL). This preference is based upon the potential need to discontinue anticoagulation should the need arise (eg, procedures, bleeding). Once the patient is no longer critically ill and the pacing wires are removed, therapeutic anticoagulation is initiated. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
         Once therapeutically anticoagulated with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         , we transition to oral
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . We prefer to use warfarin for the first several months after surgery given its ability to be monitored and its ease of reversal should bleeding complications occur. Thereafter, anticoagulation with warfarin or a direct oral anticoagulation (DOAC) is maintained indefinitely. (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Anticoagulant therapy (indefinite)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4793786">
         <span class="h2">
          Monitoring for pulmonary endarterectomy-specific complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CTEPH who undergo PTE may experience complications that are common to other types of cardiothoracic surgery (eg, arrhythmias, atelectasis, wound infection, pericardial effusions, and delirium) (see
         <a class="medical medical_review" href="/z/d/html/4401.html" rel="external">
          "Overview of the management of postoperative pulmonary complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7014.html" rel="external">
          "Postoperative mediastinitis after cardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">
          "Postoperative complications among patients undergoing cardiac surgery"
         </a>
         ). They may also experience two unique complications that can significantly impair gas exchange: pulmonary artery steal and RPE, which are discussed in the sections below. These complications can occur in isolation or together.
        </p>
        <p class="headingAnchor" id="H1664046">
         <span class="h3">
          Pulmonary artery steal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary artery steal occurs in approximately 70 percent of patients following PTE. Pulmonary artery steal refers to the postoperative redistribution of pulmonary arterial blood flow from originally well-perfused segments into the newly endarterectomized segments, with subsequent ventilation-perfusion mismatching and hypoxemia [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Pulmonary artery steal presents with nonspecific features of hypoxemic respiratory failure immediately after surgery, typically in the absence of infiltrates on imaging. Treatment is supportive (ie, low-flow or high-flow supplemental oxygen, mechanical ventilation). Pulmonary vascular steal resolves in most patients within a few days. Supplemental oxygen needs resolve within two weeks of hospital discharge [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Reperfusion pulmonary edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPE occurs in approximately 30 percent of patients following PTE. RPE is a type of high-permeability (ie, non-cardiogenic) pulmonary edema that typically occurs in areas of the lung from which proximal thromboemboli were removed [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3456.html" rel="external">
          "Noncardiogenic pulmonary edema"
         </a>
         .)
        </p>
        <p>
         RPE typically appears up to 72 hours after surgery. Presentation features include hypoxemic respiratory failure and bilateral infiltrates, ranging from mild postoperative hypoxemia to severe hemorrhagic pulmonary edema that results in profound hypoxemia and, rarely, death.
        </p>
        <p>
         We manage patients with RPE in a similar fashion to patients with acute respiratory distress syndrome (ARDS; eg, diuresis, lung protective ventilator strategy). Although not routine, small case series suggest that
         <a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">
          inhaled nitric oxide
         </a>
         may improve oxygenation in this population [
         <a href="#rid26">
          26-29
         </a>
         ]. Veno-venous extracorporeal membrane oxygenation may be required in patients who fail this approach. We do not perform prone ventilation due to the fresh sternotomy. (See
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">
          "Acute respiratory distress syndrome: Ventilator management strategies for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">
          "Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"
         </a>
         .)
        </p>
        <p>
         Predicting which patients will develop RPE is difficult. In one study, the Pulmonary Edema Predictive Scoring Index (PEPSI) was reported in patients undergoing percutaneous transluminal balloon pulmonary angioplasty (BPA) as therapy for CTEPH. PEPSI is a measure of the change in pulmonary arterial blood flow before and after angioplasty [
         <a href="#rid30">
          30
         </a>
         ]. A higher PEPSI score (cut-off value of 35.4) was associated with a higher risk of RPE. PEPSI requires greater validation before it can be routinely used to predict the risk of RPE following BPA or PTE. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Percutaneous balloon pulmonary angioplasty'
         </a>
         .)
        </p>
        <p>
         Low tidal volume ventilation or nitric oxide administration does not appear to prevent RPE [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3756882">
         <span class="h2">
          Pulmonary hemodynamics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following PTE, hemodynamic improvement in pulmonary artery pressures and pulmonary vascular resistance (PVR) is typically dramatic and immediate (
         <a class="graphic graphic_table graphicRef60924" href="/z/d/graphic/60924.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,32-34
         </a>
         ]. Most of the hemodynamic improvement occurs during the first few hours to days, with small improvements in the weeks to months thereafter. In most patients, the assessment for the degree of improvement takes place six weeks to three months after PTE, and it is rare that repeat PTE or medical therapy is considered in the early postoperative setting. (See
         <a class="local">
          'Expected course for pulmonary hemodynamics and symptoms'
         </a>
         below and
         <a class="local">
          'Residual pulmonary hypertension'
         </a>
         below.)
        </p>
        <p>
         In one study, the mean reduction in PVR in the immediate postoperative period was nearly 70 percent, and a PVR in the range of 200 to 350 dyne seconds/cm
         <sup>
          5
         </sup>
         (2.5 to 4.4 Wood units) was frequently achieved; although the higher end of this range is still in keeping with mild pulmonary hypertension (PH; eg, ≥240 dynes per second per cm-
         <sup>
          5
         </sup>
         [≥3 Wood units]) [
         <a href="#rid35">
          35
         </a>
         ]. Normalization of PVR can occur but typically only in those with lower pulmonary pressures prior to PTE.
        </p>
        <p>
         The hemodynamic improvement is associated with improvement of symptoms, physical signs, exercise capacity, functional capacity, and oxygen requirement. Symptoms, exercise, and function may continue to improve slightly over the ensuing three months. (See
         <a class="local">
          'Expected course for pulmonary hemodynamics and symptoms'
         </a>
         below.)
        </p>
        <p>
         Echocardiography demonstrates a decrease in right atrial and right ventricular chamber size, normalization of the interventricular septum, and decrease or resolution of tricuspid regurgitation [
         <a href="#rid36">
          36-39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'
         </a>
         .)
        </p>
        <p>
         Some patients have residual pulmonary hypertension, the details of which are discussed below. (See
         <a class="local">
          'Residual pulmonary hypertension'
         </a>
         below.)
        </p>
        <p>
         While occasionally needed, V-A ECMO may be required in patients who have acute decompensated right ventricular function after surgery [
         <a href="#rid22">
          22,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1043708843">
         <span class="h2">
          Perioperative mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Perioperative mortality among patients undergoing PTE for CTEPH has decreased over the last few decades and in our experience is typically 2 to 4 percent [
         <a href="#rid13">
          13,41-44
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 500 patients who had undergone PTE, perioperative mortality fell from 16 percent before 1990 to 7 percent between 1990 and 1999, and 4 percent between 1998 and 2002 [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data analysis from an international registry reported an in-hospital postoperative mortality rate of 4.7 percent between 2007 and 2009 [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study reported in-hospital mortality rates as low as 2.5 percent between 2011 and 2016 [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among low-risk patients, a perioperative mortality rate of only 1.3 percent has been reported [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         RPE and right ventricular failure due to residual PH are the most common causes of death [
         <a href="#rid1">
          1
         </a>
         ]. Other causes of perioperative mortality include cardiac arrest, multiorgan failure, uncontrollable mediastinal bleeding, sepsis, and massive pulmonary hemorrhage. (See
         <a class="local">
          'Reperfusion pulmonary edema'
         </a>
         above.)
        </p>
        <p>
         Predictors of mortality have been reported. Important predictors of perioperative mortality include [
         <a href="#rid44">
          44-49
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated PVR - Patients with preoperative PVR &lt;1,000 dynes per second per cm
         <sup>
          -5
         </sup>
         (&lt;12.5 Wood units) have an estimated mortality &lt;1.6 percent while those with a preoperative PVR ≥1,000 dynes per second per cm
         <sup>
          -5
         </sup>
         (≥12.5 Wood units) have a mortality of 4 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age – Patients older than 70 years have an estimated mortality of 8 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distal (ie, microvascular) disease – Patients with distal embolic disease have an estimated mortality of 8 percent.
        </p>
        <p>
        </p>
        <p>
         Other factors include intraoperative complications, additional cardiac procedures (eg, coronary artery bypass grafting), and co-morbidities.
        </p>
        <p class="headingAnchor" id="H2259544968">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         After pulmonary thromboendarterectomy (PTE), patients are followed long term.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We routinely see patients within one to two weeks after discharge and every six weeks to six months thereafter, where we inquire about symptoms and ensure therapeutic anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We repeat a ventilation perfusion scan and echocardiogram approximately six weeks to three months after PTE in order to establish new baseline studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with features suggestive of residual PH and patients with a postoperative mean pulmonary artery pressure ≥30 mmHg, we additionally perform right heart catheterization to determine if further interventions are indicated (eg, PH-specific therapy and/or balloon pulmonary angioplasty). (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Inoperable candidates'
         </a>
         and
         <a class="local">
          'Residual pulmonary hypertension'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          LONG TERM OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H3758002337">
         <span class="h2">
          Survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following discharge, additional deaths may be expected, approximately one-half from conditions other than progressive right ventricular failure and the remainder due to pulmonary hypertension (PH)-related issues (ie, failed PTE). The overall three-year survival is approximately 85 percent at one year but declines over time [
         <a href="#rid44">
          44,46,49
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 880 patients who underwent PTE, the overall survival was 86 percent at one year, 84 percent at three years, 79 percent at five years, and 72 percent at 10 years [
         <a href="#rid46">
          46
         </a>
         ]. Few deaths were due to right heart failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, another study of 239 patients reported the three-, five-, and ten-year survival as 84, 77, and 62 percent, respectively [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Among patients with CTEPH who survive three months post-PTE, mortality is low:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study that followed 137 patients with CTEPH who survived three months following PTE, 4 percent died from CTEPH-related causes during the four-year follow-up period [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A similar study demonstrated one- and three-year mortality rates of 1 and 6 percent, respectively [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Predictors for reduced long-term survival are poorly studied [
         <a href="#rid44">
          44,46,49
         </a>
         ]. However, one study reported that an elevated mean pulmonary artery pressure (mPAP) ≥38 mmHg and a pulmonary vascular resistance (PVR) ≥425 dynes per second per-cm
         <sup>
          -5
         </sup>
         identified patients at a higher risk of death from CTEPH [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1555277925">
         <span class="h2">
          Expected course for pulmonary hemodynamics and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemodynamic and symptomatic improvement occur in the vast majority of patients following PTE. Long-term improvement is likely due to reduced right ventricular afterload (due to a reduction in PH), resolution of postoperative anemia and deconditioning, and improved ventilation-perfusion matching as postoperative pulmonary artery steal resolves. Improvement generally persists following surgery according to studies that have followed patients for up to 24 months (
         <a class="graphic graphic_table graphicRef60924" href="/z/d/graphic/60924.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid32">
          32,33,51,52
         </a>
         ]. Most patients are New York Heart Association (NYHA) functional Class III or IV preoperatively and improve to NYHA Class I or II postoperatively (
         <a class="graphic graphic_table graphicRef52486" href="/z/d/graphic/52486.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 3
         </a>
         ). Many patients resume normal activity, including employment [
         <a href="#rid51">
          51
         </a>
         ]. A small proportion develop slowly progressive PH over several years that may warrant medical therapy. (See
         <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"
         </a>
         and
         <a class="local">
          'Residual pulmonary hypertension'
         </a>
         below.)
        </p>
        <p>
         PTE also appears to have a lasting impact on peripheral oxygen extraction and cardiac performance [
         <a href="#rid53">
          53
         </a>
         ]. One study of 20 patients who underwent serial cardiopulmonary exercise testing (CPET) reported ongoing improvement of peak oxygen uptake, ventilatory efficiency, and exercise capacity, reaching a plateau one to six months after surgery. Improved exercise capacity may be due to decreased PVR, or improved ventilation or stroke volume index [
         <a href="#rid54">
          54
         </a>
         ]. General principles of CPET are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1433.html" rel="external">
          "Exercise physiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3465.html" rel="external">
          "Cardiopulmonary exercise testing in cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1784527165">
         <span class="h2">
          Recurrent thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent acute thromboembolism is rare since these patients are indefinitely anticoagulated and if thromboembolism does occur, it is typically due to sub-therapeutic anticoagulation. Less than 0.5 percent of all patients who have undergone PTE develop recurrent thromboembolic disease, and it is equally rare that repeat PTE is required [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         For patients who do develop recurrent embolism, we suggest a three-month period of anticoagulation to allow thrombus resolution before evaluating whether a repeat endarterectomy procedure might be indicated. Management of recurrent thromboembolism while on anticoagulant therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Management of recurrence on therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4108828202">
         <span class="h2">
          Residual pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although PH normalizes in many patients following PTE, some have residual PH. Rates range from 15 to 51 percent (on average 30 percent) [
         <a href="#rid41">
          41,46,56-58
         </a>
         ]. The variation of the estimates likely reflects whether a threshold of 20 mmHg, 25 mmHg, or 30 mmHg is used to define postoperative residual PH.
        </p>
        <p>
         We use a postoperative mPAP≥30 mmHg as a plausible threshold to define which patients require consideration of additional therapies for residual PH, such as PH-specific medication and/or balloon pulmonary angioplasty (BPA) [
         <a href="#rid46">
          46
         </a>
         ]. Our practice is to perform a repeat right heart catheterization 6 to 12 weeks after the thromboendarterectomy procedure in patients with a postoperative mPAP ≥30 mmHg or those with symptoms suggestive of PH to determine if these additional interventions are indicated.
        </p>
        <p>
         Management of residual PH varies and is dependent upon the severity of the underlying PH as well as functional capacity and etiology of the PH (eg, residual distal disease or residual thromboembolism, recurrent CTEPH). In this population we consider the following principles:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with residual PH who have Class I NYHA symptoms (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 3
         </a>
         ), we typically observe them clinically for symptoms of progressive disease, which, if present, should prompt further investigation for recurrent CTEPH. (See
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with residual PH who have NYHA functional Class II to IV symptoms (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 3
         </a>
         ) who are not suitable for additional surgery, we typically initiate PH-specific therapy. The initiation of PH-specific therapy requires a detailed assessment by a specialist in PH in a PH center. (See
         <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatively, preliminary data suggest that BPA with or without PH-specific therapy may be an option in this population if accessible target lesions are identified on pulmonary angiography, the details of which are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Percutaneous balloon pulmonary angioplasty'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Combined therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with refractory PH following PTE, transplantation may be the only option. PH-specific therapy may be needed as a bridge to transplantation. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Double lung transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who experience recurrent thromboembolism associated with PH, we re-evaluate patients for repeat PTE. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Evaluation for pulmonary thromboendarterectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Repeat PTE has been performed successfully. The morbidity and mortality of the second surgery is comparable to the primary procedure, but the improvement in hemodynamics is typically less impressive [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         It is possible for patients with residual PH to achieve functional improvement and a survival equivalent to those who do not have persistent PH following surgery [
         <a href="#rid58">
          58
         </a>
         ]. However, the outcomes vary depending on the therapy chosen, their response to medications, and degree of residual PH.
        </p>
        <p>
         Residual PH is unclear but likely due to distal (ie, surgically inaccessible) thromboemboli or irreversible vasculopathy. One imaging study reported residual disease in 45 percent of patients, but subsegmental pulmonary vasculature was only abnormal in 20 percent; this suggested that residual undetectable microvascular lesions may contribute to PH in this population [
         <a href="#rid59">
          59
         </a>
         ]. Alternatively, irreversible vasculopathy may have contributed to PH, more than what was originally suspected at the time of the PTE evaluation.
        </p>
        <p class="headingAnchor" id="H774368906">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">
          "Society guideline links: Pulmonary hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1663888">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary thromboendarterectomy (PTE) is the only definitive therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Selecting ideal candidates for PTE should occur at a center experienced in the care of these patients. The decision to proceed with PTE is based upon the location and extent of chronic thromboembolic obstruction, the associated hemodynamic impairment, and comorbidities that might contribute to the risk of surgery. (See
         <a class="local">
          'Patient selection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We evaluate patients with CTEPH in whom PTE is planned for general, cardiac, pulmonary, and other factors that may contribute to the risk of PTE. Specific to PTE are the following (see
         <a class="local">
          'Specific preoperative assessment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are at risk for coronary artery disease in whom PTE is planned, we perform coronary angiography prior to surgery. (See
         <a class="local">
          'Coronary angiography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest not routinely placing an inferior vena caval (IVC) filter (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We sometimes place an IVC filter in patients with a higher than usual risk of thromboembolic recurrence in the perioperative period; in such patients, we place a retrievable filter several days prior to surgery and use the transjugular approach. (See
         <a class="local">
          'Inferior vena cava filter placement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PTE typically involves a median sternotomy and cardiopulmonary bypass with periods of hypothermic circulatory arrest. The main, lobar, and segmental branches of typically both pulmonary arteries are targeted for removal of chronic thrombus. An entire unilateral endarterectomy can usually be accomplished by an experienced surgeon within 20 minutes of hypothermic circulatory arrest. Additional surgeries that are indicated, such as atrial septal defect repair, coronary bypass grafting, or valve replacement, are performed after dissection and rewarming. Alternative techniques have been explored, but none have proven superior to the traditional technique. (See
         <a class="local">
          'Surgical technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with CTEPH who undergo PTE should undergo vigilant postoperative monitoring because the postoperative course can be complex, and it is the period of greatest mortality. We monitor for the typical postoperative complications that are common to other types of cardiothoracic surgery (eg, arrhythmias, atelectasis, wound infection, pericardial effusions, and delirium). (See
         <a class="medical medical_review" href="/z/d/html/4401.html" rel="external">
          "Overview of the management of postoperative pulmonary complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7014.html" rel="external">
          "Postoperative mediastinitis after cardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">
          "Postoperative complications among patients undergoing cardiac surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Monitoring for issues specific to PTE include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All patients require intensive care unit (ICU) admission and are typically intubated and mechanically ventilated. Most patients have a pulmonary artery catheter in place (no balloon inflation) as well as a Foley catheter, temporary transcutaneous pacing wires, an arterial catheter, and one or more mediastinal tubes. We perform daily assessment with physical examination, routine laboratories, coagulation studies, and, if indicated, an electrocardiogram or chest radiograph. (See
         <a class="local">
          'Intensive care unit postoperative care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For the majority of patients, we suggest initiating pharmacologic thromboprophylaxis postoperatively, provided there are no contraindications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We typically start thromboprophylaxis 8 to 12 hours after PTE, provided the mediastinal output has decreased to approximately 30 mL/hour. Agent choice is center-specific. We suggest intravenous
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         targeting an anti-Xa level in the low therapeutic range (0.3 to 0.5 international units/mL) as our preferred method (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This preference is based upon the potential need to discontinue anticoagulation should the need arise (eg, procedures, bleeding). Once the patient is no longer critically ill and the pacing wires removed, we initiate therapeutic anticoagulation. Choice of agent for long-term anticoagulation is discussed separately. (See
         <a class="local">
          'Venous thromboembolism prophylaxis and resumption of therapeutic anticoagulation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Anticoagulant therapy (indefinite)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two complications that are unique to PTE can occur in isolation or together. These are pulmonary artery steal and reperfusion pulmonary edema. Both conditions are typically self-limiting and treated supportively but occasionally can result in profound hypoxemia, pulmonary hemorrhage, and rarely death. We use strategies that are similar to those used in patients with acute respiratory distress syndrome, the details of which are discussed separately. (See
         <a class="local">
          'Monitoring for pulmonary endarterectomy-specific complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">
          "Acute respiratory distress syndrome: Ventilator management strategies for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">
          "Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Improvement in pulmonary hemodynamics is typically dramatic and immediate following PTE, with marked reductions in pulmonary artery pressures and pulmonary vascular resistance (PVR) (
         <a class="graphic graphic_table graphicRef60924" href="/z/d/graphic/60924.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pulmonary hemodynamics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The perioperative mortality among patients undergoing PTE for CTEPH is typically 2 to 4 percent, with lower rates in low-risk patients (eg, those with PVR &lt;1000 dynes per second per cm
         <sup>
          -5
         </sup>
         [&lt;12.5 Wood units], no comorbidities) and higher rates in others (eg, those with a PVR ≥1000 dynes per second per cm
         <sup>
          -5
         </sup>
         [≥12.5 Wood units], older age &gt;70 years, distal disease), and those who undergo additional cardiac procedures or develop complications of thoracic surgery. (See
         <a class="local">
          'Perioperative mortality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The long-term beneficial effects of PTE include continued hemodynamic and symptomatic improvement, improved functional class (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 3
         </a>
         ), and probably, decreased mortality. The overall three-year survival is approximately 85 percent at one year but declines over time. Recurrent thromboembolism is rare and often relates to subtherapeutic anticoagulation. (See
         <a class="local">
          'Long term outcomes'
         </a>
         above and
         <a class="local">
          'Expected course for pulmonary hemodynamics and symptoms'
         </a>
         above and
         <a class="local">
          'Survival'
         </a>
         above and
         <a class="local">
          'Recurrent thromboembolism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somewhere between 15 to 51 percent of patients have residual PH (on average 30 percent). Management of residual PH varies and is dependent upon the severity of the underlying PH as well as functional capacity and etiology of the PH. Further details regarding PH-specific therapy are provided separately. (See
         <a class="local">
          'Residual pulmonary hypertension'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Pulmonary hypertension-specific therapy'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banks DA, Pretorius GV, Kerr KM, Manecke GR. Pulmonary endarterectomy: Part II. Operation, anesthetic management, and postoperative care. Semin Cardiothorac Vasc Anesth 2014; 18:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Perrot M, Gopalan D, Jenkins D, et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. J Heart Lung Transplant 2021; 40:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thistlethwaite PA, Auger WR, Madani MM, et al. Pulmonary thromboendarterectomy combined with other cardiac operations: indications, surgical approach, and outcome. Ann Thorac Surg 2001; 72:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey AK, Lee NS, Marsal J, et al. Evaluation of Routine Coronary Angiography Before Pulmonary Thromboendarterectomy. Ann Thorac Surg 2021; 111:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamieson SW, Auger WR, Fedullo PF, et al. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993; 106:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zund G, Prêtre R, Niederhäuser U, et al. Improved exposure of the pulmonary arteries for thromboendarterectomy. Ann Thorac Surg 1998; 66:1821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg 2008; 14:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madani MM, Jamieson SW. Technical advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 2006; 18:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madani MM. Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension: Pulmonary Thromboendarterectomy. Methodist Debakey Cardiovasc J 2016; 12:213.
          </a>
         </li>
         <li class="breakAll">
          https://www.sciencedirect.com/science/article/abs/pii/S1522294219300935?via%3Dihub (Accessed on March 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagl C, Khaladj N, Peters T, et al. Technical advances of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Eur J Cardiothorac Surg 2003; 23:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson B, Tsui SS, Dunning J, et al. Pulmonary endarterectomy is possible and effective without the use of complete circulatory arrest--the UK experience in over 150 patients. Eur J Cardiothorac Surg 2008; 33:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikus PM, Mikus E, Martìn-Suàrez S, et al. Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results. Eur J Cardiothorac Surg 2008; 34:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes TM, Kim NH, Kerr KM, et al. Distal vessel pulmonary thromboendarterectomy: Results from a single institution. J Heart Lung Transplant 2023; 42:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fedullo PF, Auger WR, Dembitsky WP. Postoperative management of the patient undergoing pulmonary thromboendarterectomy. Semin Thorac Cardiovasc Surg 1999; 11:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishisaka Y, Watanabe A, Takagi H, et al. Use of Perioperative Extracorporeal Membranous Oxygenation in Pulmonary Endarterectomy Cases: A Systematic Review and Meta-Analysis. J Intensive Care Med 2023; 38:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olman MA, Auger WR, Fedullo PF, Moser KM. Pulmonary vascular steal in chronic thromboembolic pulmonary hypertension. Chest 1990; 98:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser KM, Metersky ML, Auger WR, Fedullo PF. Resolution of vascular steal after pulmonary thromboendarterectomy. Chest 1993; 104:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levinson RM, Shure D, Moser KM. Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy. Am Rev Respir Dis 1986; 134:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KC, Cho YL, Lee SY. Reperfusion pulmonary edema after pulmonary endarterectomy. Acta Anaesthesiol Sin 2001; 39:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gårdebäck M, Larsen FF, Rådegran K. Nitric oxide improves hypoxaemia following reperfusion oedema after pulmonary thromboendarterectomy. Br J Anaesth 1995; 75:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imanaka H, Miyano H, Takeuchi M, et al. Effects of nitric oxide inhalation after pulmonary thromboendarterectomy for chronic pulmonary thromboembolism. Chest 2000; 118:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinelli G, Mertes PM, Carteaux JP, et al. Inhaled nitric oxide as an adjunct to pulmonary thromboendarterectomy. Ann Thorac Surg 1996; 61:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inami T, Kataoka M, Shimura N, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv 2013; 6:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bates DM, Fernandes TM, Duwe BV, et al. Efficacy of a Low-Tidal Volume Ventilation Strategy to Prevent Reperfusion Lung Injury after Pulmonary Thromboendarterectomy. Ann Am Thorac Soc 2015; 12:1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser KM, Daily PO, Peterson K, et al. Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension. Immediate and long-term results in 42 patients. Ann Intern Med 1987; 107:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser KM, Spragg RG, Utley J, Daily PO. Chronic thrombotic obstruction of major pulmonary arteries. Results of thromboendarterectomy in 15 patients. Ann Intern Med 1983; 99:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoro-Sajer N, Marta G, Gerges C, et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax 2014; 69:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auger WR, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med 2009; 30:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadeghi HM, Kimura BJ, Raisinghani A, et al. Does lowering pulmonary arterial pressure eliminate severe functional tricuspid regurgitation? Insights from pulmonary thromboendarterectomy. J Am Coll Cardiol 2004; 44:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thistlethwaite PA, Jamieson SW. Tricuspid valvular disease in the patient with chronic pulmonary thromboembolic disease. Curr Opin Cardiol 2003; 18:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dittrich HC, Nicod PH, Chow LC, et al. Early changes of right heart geometry after pulmonary thromboendarterectomy. J Am Coll Cardiol 1988; 11:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casaclang-Verzosa G, McCully RB, Oh JK, et al. Effects of pulmonary thromboendarterectomy on right-sided echocardiographic parameters in patients with chronic thromboembolic pulmonary hypertension. Mayo Clin Proc 2006; 81:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelnour-Berchtold E, Donahoe L, McRae K, et al. Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure. J Heart Lung Transplant 2022; 41:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korsholm K, Andersen A, Mellemkjær S, et al. Results from more than 20 years of surgical pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension in Denmark. Eur J Cardiothorac Surg 2017; 52:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vistarini N, Morsolini M, Klersy C, et al. Pulmonary endarterectomy in the elderly: safety, efficacy and risk factors. J Cardiovasc Med (Hagerstown) 2016; 17:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannon JE, Su L, Kiely DG, et al. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation 2016; 133:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg 2012; 94:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Armini AM, Morsolini M, Mattiucci G, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2014; 148:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delcroix M, Lang I, Pepke-Zaba J, et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation 2016; 133:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corsico AG, D'Armini AM, Cerveri I, et al. Long-term outcome after pulmonary endarterectomy. Am J Respir Crit Care Med 2008; 178:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999; 160:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archibald CJ, Auger WR, Fedullo PF. Outcome after pulmonary thromboendarterectomy. Semin Thorac Cardiovasc Surg 1999; 11:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwase T, Nagaya N, Ando M, et al. Acute and chronic effects of surgical thromboendarterectomy on exercise capacity and ventilatory efficiency in patients with chronic thromboembolic pulmonary hypertension. Heart 2001; 86:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surie S, van der Plas MN, Marcus JT, et al. Effect of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension on stroke volume response to exercise. Am J Cardiol 2014; 114:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mo M, Kapelanski DP, Mitruka SN, et al. Reoperative pulmonary thromboendarterectomy. Ann Thorac Surg 1999; 68:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thistlethwaite PA, Kemp A, Du L, et al. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006; 131:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freed DH, Thomson BM, Berman M, et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg 2011; 141:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braams NJ, Ruigrok D, Schokker MGM, et al. Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2020; 39:248.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8255 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21330453" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21268727" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25005856" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pulmonary endarterectomy: Part II. Operation, anesthetic management, and postoperative care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545969" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33334946" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : ERS statement on chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320113" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34420851" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11465167" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pulmonary thromboendarterectomy combined with other cardiac operations: indications, surgical approach, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32896544" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evaluation of Routine Coronary Angiography Before Pulmonary Thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26318161" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8320990" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9875807" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Improved exposure of the pulmonary arteries for thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18989242" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Technique and outcomes of pulmonary endarterectomy surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185187" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Technical advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28289496" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension: Pulmonary Thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28289496" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension: Pulmonary Thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12754032" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Technical advances of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18077177" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary endarterectomy is possible and effective without the use of complete circulatory arrest--the UK experience in over 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18554921" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37024310" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Distal vessel pulmonary thromboendarterectomy: Results from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10378861" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Postoperative management of the patient undergoing pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37226426" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Use of Perioperative Extracorporeal Membranous Oxygenation in Pulmonary Endarterectomy Cases: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2245685" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pulmonary vascular steal in chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8222803" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Resolution of vascular steal after pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3789523" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11475183" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Reperfusion pulmonary edema after pulmonary endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8672337" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Nitric oxide improves hypoxaemia following reperfusion oedema after pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893357" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effects of nitric oxide inhalation after pulmonary thromboendarterectomy for chronic pulmonary thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8561567" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Inhaled nitric oxide as an adjunct to pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23769649" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241077" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy of a Low-Tidal Volume Ventilation Strategy to Prevent Reperfusion Lung Injury after Pulmonary Thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3631790" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension. Immediate and long-term results in 42 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6614679" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Chronic thrombotic obstruction of major pulmonary arteries. Results of thromboendarterectomy in 15 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052543" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19634086" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15234420" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Does lowering pulmonary arterial pressure eliminate severe functional tricuspid regurgitation? Insights from pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12652215" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Tricuspid valvular disease in the patient with chronic pulmonary thromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3356839" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Early changes of right heart geometry after pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16770978" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effects of pulmonary thromboendarterectomy on right-sided echocardiographic parameters in patients with chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35370035" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18292468" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602267" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21969018" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28591785" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Results from more than 20 years of surgical pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26702594" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pulmonary endarterectomy in the elderly: safety, efficacy and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27052413" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22626752" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25129589" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26826181" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18556630" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term outcome after pulmonary endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10430723" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term outcome after pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10378860" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcome after pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11454839" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Acute and chronic effects of surgical thromboendarterectomy on exercise capacity and ventilatory efficiency in patients with chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24819907" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effect of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension on stroke volume response to exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10585057" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Reoperative pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17420352" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Predictors of outcome in chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434258" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471039" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31866175" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
